The U.S. P2Y12 Inhibitors Market, by Drug (Clopidogrel, Ticlopidine, Ticagrelor, Prasugrel, Cangrelor, and Others), by Route of Administration (Oral and Intravenous), by Application (Angioplasty, Arterial Thrombosis, Percutaneous Coronary Interventions, Myocardial Infarction, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) is estimated to be valued at US$ 215.7 Mn in 2021, and is expected to exhibit a CAGR of 3.8% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Key players in the market focusing on inorganic growth strategies such as agreement is expected to propel growth of the U.S. P2Y12 inhibitors market over the forecast period. For instance, Antares Pharma, Inc. a specialty pharmaceutical company, announced that it had entered into a global agreement with Idorsia Pharmaceuticals Ltd., a company which develops and manufactures pharmaceutical, biological, and diagnostic products, to develop a novel, drug-device product combining selatogrel, Idorsia’s potent, fast-acting, and highly selective P2Y12 receptor antagonist under development, with the Antares subcutaneous QuickShot auto injector.
U.S. P2Y12 Inhibitors Market– Impact of Coronavirus (COVID-19) Pandemic
Governments and government agencies globally are taking various initiatives to combat the spread of COVID-19. For instance, in May 2020, the Centers for Disease Control and Prevention (CDC) started working with the All-of-Government and All-of-America approach to increase testing capacity, improve case detection, and contact tracing across all the U.S. states and re-open the country. Moreover, the CDC is working with the U.S. states and local partners to define the circumstances, where testing of asymptomatic people is likely to be helpful in controlling the pandemic, as well as it is the best application of surveillance serologic testing. Furthermore, the CDC is supporting the improvement of current data infrastructure, and the development and integration of digital/technology solutions in various healthcare solutions, in order to ensure timely and transparent communication with all citizens in the U.S. including daily new cases, hospitalizations, use of intensive care units (ICU), and mortality by country and/or zip code. Furthermore, on April 23, 2021, the U.S. Centers for Disease Control (CDC) and the U.S Food and Drug Administration (FDA) stated that the vaccination drives with Johnson & Johnson’s company resumed the adults residing in the U.S. Various leading pharmaceutical companies and technological companies are collaborating with the U.S. government for the faster clinical development of vaccines for prevention of the COVID-19 infections in the U.S. For instance, in July 2020, IQVIA, a clinical service company, and Astra Zeneca, a pharmaceutical company, announced the collaboration with the U.S. government for Operation Warp Speed project. The project was focused on boosting clinical studies of the COVID-19 vaccine in the U.S. and include an expansive subject study, which was expected to begin enrolling participants in 4th quarters 2020 and will leverage IQVIA’s Virtual Trial solutions including Study Hub.
Browse 9 Market Data Tables and 17 Figures spread through 156 Pages and in-depth TOC on “P2Y12 Inhibitors Market”- U.S. Forecast to 2028, U.S. P2Y12 Inhibitors Market, by Drug (Clopidogrel, Ticlopidine, Ticagrelor, Prasugrel, Cangrelor, and Others), by Route of Administration (Oral and Intravenous), by Application (Angioplasty, Arterial Thrombosis, Percutaneous Coronary Interventions, Myocardial Infarction, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
To know the latest trends and insights prevalent in the U.S. P2Y12 Inhibitors Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/us-p2y12-inhibitors-market-4983
Moreover, increasing prevalence of stroke is also expected to aid in growth of the U.S. P2Y12 inhibitors market over the forecast period. For instance, according to data published by Centers for Disease Control and Prevention, stated that Stroke is a leading cause of death in the U.S. and is a major cause of serious disability for adults. About 795,000 people in the U.S. have a stroke each year.
Key Takeaways of the U.S. P2Y12 Inhibitors Market:
- The U.S. P2Y12 Inhibitors Market is expected to exhibit a CAGR of 3.8% during the forecast period due to rising geriatric population, which is expected to boost growth of the market. For instance, according to article published by Administration for Community Living in May 2021, stated that the population age 65 and older numbered 54.1 million in 2019, in the U.S.
- On the basis of application, angioplasty segment is estimated to hold largest market share in the U.S. P2Y12 inhibitors market over the forecast period owing to increasing prevalence of cardiovascular disease. For instance, according to data published by New York State Government, stated that about 7.8% of adults in New York State reported they have had a heart attack, angina/coronary heart disease, or stroke in 2018. Moreover, one out of five (20%) New Yorker aged 65 and older reported having some type of cardiovascular disease in 2018.
- Among the distribution channel, hospital pharmacies is estimated to hold dominant position in U.S. P2Y12 inhibitors market in Increase in the healthcare expenditure by various healthcare regulatory organizations in the U.S. in the past years is expected to drive the segment growth. For instance, according to the U.S. Centers for Medicare and Medicaid
Services’ 2019 findings on the National Health Expenditure (NHE), hospital expenditure grew by 4.6% to US$ 3.8 trillion in 2019, compared to the previous year (2018). Additionally, prescription drug expenditure increased by 5.7% to US$ 369.7 billion in 2019, faster than the 3.8% growth in 2018.
- Major players operating in the S. P2Y12 inhibitors market include Mylan N.V., Bristol-Myers Squibb, Dr Reddy's Laboratories, Teva Pharmaceuticals USA, Inc., AstraZeneca, Genentech, Eli Lilly and Company, Panacea Biotec, CHIESI USA, Inc., Lupin, Cipla, and Biocon
